A SUR1/Kir6.2 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mitiglinide (calcium salt)

Item No. 30693

Technical Information
Formal Name
(αS,3aR,7aS)-octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid, hemicalcium salt
CAS Number
145525-41-3
Synonyms
  • KAD-1229
  • S21403
Molecular Formula
C19H24NO3 • 1/2Ca
Formula Weight
Purity
≥98% (mixture of isomers)
Formulation
A crystalline solid
Chloroform: slightly solubleDMF: slightly solubleDMSO: slightly solubleMethanol: slightly soluble
λmax
239 nm
SMILES
O=C(C[C@H](CC1=CC=CC=C1)C([O-])=O)N2C[C@@]3([H])CCCC[C@@]3([H])C2.O=C(C[C@H](CC4=CC=CC=C4)C([O-])=O)N5C[C@@]6([H])CCCC[C@@]6([H])C5.[Ca+2]
InChi Code
InChI=1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17-;/m00./s1
InChi Key
PMRVFZXOCRHXFE-FMEJWYFOSA-L
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Mitiglinide is an inhibitor of sulfonylurea receptor 1 (SUR1) linked to ATP-sensitive potassium channel Kir6.2 (IC50 = 4 nM).1 It is selective for SUR1/Kir6.2 over SUR2A/Kir6.2 and SUR2B/Kir6.2 channels (IC50s = 3 and 5 µM, respectively). Mitiglinide induces insulin release in HIT-T15 insulinoma cells and isolated mouse pancreatic islets when used at a concentration of 100 µM.2 Oral administration of mitiglinide (1, 3, and 10 mg/kg) increases postprandial plasma insulin levels and inhibits postprandial increases in plasma glucose levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Reimann, F., Proks, P., and Ashcroft, F.M. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br. J. Pharmacol. 132(7), 1542-1548 (2001).

    2. Ohnota, H., Koizumi, T., Tsutsumi, N., et alNovel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: Comparison of effects between KAD-1229 and gliclazide. J. Pharmacol. Exp. Ther. 269(2), 489-495 (1994).

    3. Ohnota, H., Kitamura, T., Kinukawa, M., et alA rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn. J. Pharmacol. 71(4), 315-323 (1996).